621 related articles for article (PubMed ID: 25661699)
1. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
Zhou C; Zhou J; Han N; Liu Z; Xiao B; Yin J
Int Immunopharmacol; 2015 Mar; 25(1):218-28. PubMed ID: 25661699
[TBL] [Abstract][Full Text] [Related]
2. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
3. Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation.
Shi L; Shi L; Zhang H; Hu Z; Wang C; Zhang D; Song G
Mol Med Rep; 2013 Aug; 8(2):439-45. PubMed ID: 23754536
[TBL] [Abstract][Full Text] [Related]
4. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
5. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats.
Qin R; Zhang J; Li C; Zhang X; Xiong A; Huang F; Yin Z; Li K; Qin W; Chen M; Zhang S; Liang L; Zhang H; Nie H; Ye W
Arch Pharm Res; 2012 Jul; 35(7):1241-50. PubMed ID: 22864747
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters.
Guo F; Huang C; Liao X; Wang Y; He Y; Feng R; Li Y; Sun C
Mol Nutr Food Res; 2011 Dec; 55(12):1809-18. PubMed ID: 22038976
[TBL] [Abstract][Full Text] [Related]
8. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
Jiang Y; Chen L; Wang H; Narisi B; Chen B
J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
[TBL] [Abstract][Full Text] [Related]
9. [Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats].
Zheng LY; Pan JQ; Lv JH
Zhongguo Zhong Yao Za Zhi; 2008 Oct; 33(20):2385-90. PubMed ID: 19157135
[TBL] [Abstract][Full Text] [Related]
10. [Effects of Electroacupunctrue Combined with Dietary Control on Peroxisome Proliferator-activa- ted Receptor-α, and Liver Fatty Acid-binding Protein Levels in Non-alcoholic Fatty Liver Disease Rats].
Zhang Y; Tang CL; Tian Y; Yuan HZ; Yang H; Tang NZ; Gao RQ; Cao J
Zhen Ci Yan Jiu; 2015 Oct; 40(5):345-51. PubMed ID: 26669188
[TBL] [Abstract][Full Text] [Related]
11. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
[TBL] [Abstract][Full Text] [Related]
12. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
13. Prevention and treatment effect of total flavonoids in Stellera chamaejasme L. on nonalcoholic fatty liver in rats.
Wang Y; Li JY; Han M; Wang WL; Li YZ
Lipids Health Dis; 2015 Aug; 14():85. PubMed ID: 26242978
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism.
Yin Y; Yu Z; Xia M; Luo X; Lu X; Ling W
Eur J Clin Invest; 2012 Nov; 42(11):1189-96. PubMed ID: 22958216
[TBL] [Abstract][Full Text] [Related]
15. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
16. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
[TBL] [Abstract][Full Text] [Related]
17. Effect of starvation on hepatic acyl-CoA synthetase, carnitine palmitoyltransferase-I, and acetyl-CoA carboxylase mRNA levels in rats.
Ryu MH; Daily JW; Cha YS
Nutrition; 2005 Apr; 21(4):537-42. PubMed ID: 15811777
[TBL] [Abstract][Full Text] [Related]
18. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
[TBL] [Abstract][Full Text] [Related]
19. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
20. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
Liu Q; Pan R; Ding L; Zhang F; Hu L; Ding B; Zhu L; Xia Y; Dou X
Int Immunopharmacol; 2017 Aug; 49():132-141. PubMed ID: 28577437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
